This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Esense-Lab Ltd Appoints Maayan Bar as External Directors CI
ESense Lab : ESsense-lab Applies to Delist from Australian Bourse MT
ESense lab : Widens 2020 Loss as Revenue Falls, Financial Expenses Jump MT
Esense-Lab Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
ESense-Lab Limited Provides Further Update on Research Agreement with Israeli MOH CI
Esense lab : Secures Funds for Operational Expenditure, Working Capital MT
ESense-Lab Ltd Announces Executive Changes CI
ESense lab : Moves Toward Commercialization of Alcohol-Free Sanitizer MT
ESense-Lab Ltd Provides Update on Research Agreement with Israeli Ministry of Health CI
Esense-Lab Ltd Reports Earnings Results for the Half Year Ended June 30, 2020 CI
ESense-Lab Ltd Signs A Research Agreement with the Israeli Ministry of Health to Commence A Joint Research Project CI
Esense-Lab Ltd Announces Change in Registered Office Address CI
ESense-Lab Ltd Announces Executive Changes, Effective July 6, 2020 CI
ESense-Lab Ltd Announces Board Changes CI
ESense-Lab Ltd announced that it has received AUD 1.145 million in funding from Everblu Capital Pty. Ltd. CI
ESense-Lab Limited Enters into Binding Joint Venture Agreement with Sassey Pty Ltd CI
ESense-Lab Limited Signs JV Agreement with Anc Enterprises Ltd to Develop and Sell New Products CI
ESense-Lab Ltd Announces Resignation of Amit Edri, Director CI
ESense-Lab Ltd Enters into Letter of Intent with SeaLaria Ltd CI
ESense-Lab Ltd announced that it expects to receive AUD 1.145 million in funding from Everblu Capital Pty. Ltd. CI
ESense-Lab Limited Announces Resignation of Mike Edwards as Director CI
ESense-Lab Ltd Announces Management Changes CI
Esense-Lab Limited Reports Earnings Results for the Full Year Ended December 31, 2019 CI
ESense-Lab Limited Announces Executive Changes CI
Esense Announces the Appointment of Dr James Ellingford as Director Effective from 13 January 2020 CI
Chart eSense-Lab Ltd
More charts
Esense-Lab Ltd is an Israel-based pharmaceutical technology company. The Company re-engineers cannabis into a virtual plant, namely terpene, a naturally occurring chemical compounds that generate the flavor and fragrance synthesized by plants. Tarpene can be used both for medicinal purposes and for the production of cannabis-based consumer products. The Company mainly serves the legal cannabis and para-cannabis markets. It also serves the: e-liquid market; pharmaceuticals market, creating on demand customized profiles and personalized medicine, as well as rare plants market, providing sustainability to rare and sought after plants such as ginseng and saffron. Its cannabis terpenes address the cannabis edibles, e-liquids and energy drinks, as well as the essential oils markets.
More about the company
  1. Stock Market
  2. Equities
  3. ESE Stock
  4. News eSense-Lab Ltd
  5. eSense lab : Widens 2020 Loss as Revenue Falls, Financial Expenses Jump